Pseudotyped Lentivirus Packaging Cell for Dendritic Cell Targeting
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for immunization, particularly for diseases like HIV/AIDS, malaria, and cancer, are inefficient and labor-intensive due to the need for ex vivo generation and loading of dendritic cells, which limits their applicability and effectiveness in inducing reliable anti-tumor immunity.
Innovation Solution
A recombinant virus is used to deliver a polynucleotide to dendritic cells expressing DC-SIGN, utilizing a targeting molecule such as a modified viral glycoprotein to specifically bind DC-SIGN, allowing for in vivo antigen loading and activation of dendritic cells, thereby generating an immune response.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If ex vivo generation and loading of dendritic cells is used, then antigen-specific immune responses can be induced, but the process becomes labor-intensive and less efficient
Solution Approach 1:
The patent enables dendritic cells to perform self-loading of antigens in vivo through direct injection of antigen and viral transduction, eliminating the need for external laboratory processing. The cells autonomously capture, process, and present antigens within the body, transforming a manual ex vivo process into an autonomous in vivo system.
Solution Approach 2:
The patent extracts the labor-intensive ex vivo generation and loading steps from the immunization process, retaining only the essential outcome of antigen-specific immune response induction. By removing the manual processing环节 and replacing it with in vivo transduction, the system achieves the same immunological effect with significantly reduced operational complexity.
2Measurement precision
If recombinant virus with targeting molecule is used, then specific targeting of dendritic cells is achieved, but virus production complexity increases
Solution Approach 1:
The patent applies local quality by endowing the virus with a specific targeting function (DC-SIGN binding) only where needed on the viral surface, while the rest of the viral structure remains standard. This localized modification allows specific dendritic cell targeting without requiring complete redesign of the entire viral system, balancing specificity with production feasibility.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enables efficient and specific targeting of dendritic cells in vivo, inducing antigen-specific immune responses, which can be used for immunotherapy and vaccination, potentially improving outcomes for diseases like cancer and HIV/AIDS.
Implementation Method 1
utilizing a targeting molecule such as a modified viral glycoprotein to specifically bind DC-SIGN
Implementation Method 2
A recombinant virus is used to deliver a polynucleotide to dendritic cells expressing DC-SIGN
Data Source
AI summary
Methods and compositions are provided for delivery of a polynucleotide encoding a gene of interest, typically an antigen, to a dendritic cell (DC). The virus envelope comprises a DC-SIGN specific targeting molecule. The methods and related compositions can be used to treat patients suffering from a wide range of conditions, including infection, such as HIV/AIDS, and various types of cancers.